Skip to main content
. 2020 Dec;98(6):739–750. doi: 10.1124/mol.119.119206

Fig. 2.

Fig. 2.

RGS9-2 forms distinct complexes in the striatum depending on the MOR agonist administered and the duration of treatment. (A) RGS9-2 complexes in the striatum following treatment with acute morphine. (B) RGS9-2 complexes in the striatum following treatment with methadone or fentanyl. (C) RGS9-2 complexes in the striatum following chronic morphine treatment (four consecutive days). GRK-2, G protein–coupled receptor kinase 2; PLC, phospholipase C. Figure summarizes findings from Psifogeorgou et al. (2011).